General
Preferred name
SEMAXANIB
Synonyms
SU 5416 ()
SU5416 ()
SU 5416 (Semaxinib) ()
Romiplostim ()
Semaxinib ()
Semaxanib (SU5416) ()
(Z)-Semaxinib ()
NSC-696819 ()
SU-5416 ()
SU005416 ()
P&D ID
PD002610
CAS
204005-46-9
194413-58-6
Tags
available
drug
Drug indication
Renal cell carcinoma
Thrombocytopenia
Multiple myeloma
Myelodysplastic syndrome
Drug Status
approved
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Semaxanib was a precursor in the development of the next generation kinase inhibitor ultimately approved as . (GtoPdb)
DESCRIPTION Semaxinib (SU5416) is a potent and selective inhibitor of VEGFR (Flk-1/KDR) with an IC50 of 1.23 ¦ÌM[1].
PRICE 109
DESCRIPTION (Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 ??M), 20-fold more selective for VEGFR over PDGFR??, no inhibition for FGFR, InsR, and EGFR. (Z)-Semaxinib is a quinolone derivative with potential antineoplastic activity.
DESCRIPTION Investigated for use/treatment in colorectal cancer and lung cancer. (PKIDB)
DESCRIPTION ACAT inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION VEGFR inhibitor. Also inhibits KIT, RET, MET and FLT3 (Tocriscreen Plus)
DESCRIPTION Potent and selective VEGFR PTK inhibitor; inhibits VEGF-induced angiogenesis (LOPAC library)
DESCRIPTION VEGFR inhibitor. Also inhibits KIT, RET, MET and FLT3 (Tocriscreen Total)
DESCRIPTION (Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for FGFR, InsR, and EGFR. (Z)-Semaxinib is a quinolone derivative with potential antineoplastic activity. (TargetMol Bioactive Compound Library)
Cell lines
7
Organisms
3
Compound Sets
24
AdooQ Bioactive Compound Library
A12437
Cayman Chemical Bioactives
13342
ChEMBL Drugs
CHEMBL276711
Concise Guide to Pharmacology 2017/18
5056
Concise Guide to Pharmacology 2019/20
5056
Concise Guide to Pharmacology 2021/22
5056
Concise Guide to Pharmacology 2023/24
5056
Drug Repurposing Hub
DrugBank
DB06436
DrugMAP
DM3U7SZ
DrugMAP Approved Drugs
DM3U7SZ
EU-OPENSCREEN Bioactive Compound Library
EOS101644
Guide to Pharmacology
5056
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL276711
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL276711
MedChem Express Bioactive Compound Library
HY-10374
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
semaxanib-su5416
TargetMol Bioactive Compound Library
T2496
Tocris Bioactive Compound Library
3037
Tocriscreen Plus
3037
Tocriscreen Total
External IDs
33
Properties
(calculated by RDKit )
Molecular Weight
238.11
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
2
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
2
cLogP
3.12
TPSA
44.89
Fraction CSP3
0.13
Chiral centers
0.0
Largest ring
6.0
QED
0.74
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzyme-Linked Receptors
Selectivity
VEGFR PTK
Target
VEGFR2/Flk1
FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET
KDR
Primary Target
VEGFR
MOA
Inhibitor
VEGFR inhibitor
Pathway
Protein Tyrosine Kinase/RTK
Angiogenesis
Tyrosine Kinase/Adaptors
Source data